Ultragenyx Pharmaceutical Inc.: enters into agreement to sell PRV for $210,000,000

What happened Ultragenyx Pharmaceutical Inc. filed an 8-K reporting that on Oct 6, 2026 it entered into an asset purchase agreement to sell a Rare Pediatric Disease Priority Review Voucher (PRV). The PRV was awarded by the U.S. Food and Drug Administration on Aug 19, 2026 upon approval of GENGLYCOS™ (pariglasgene brecaparvovec-opnr), also known as DTX401, for adult and pediatric patients eight years and older with glycogen storage disease type Ia (GSDIa). Under the PRV asset purchase agreement, the buyer agreed to pay the Company $210,000,000 in cash at closing.

Key details

• The PRV was awarded by the FDA on Aug 19, 2026 in connection with approval of GENGLYCOS™ (DTX401).
• Buyer payment: $210,000,000 payable in cash upon closing.
• Pursuant to a patent license agreement with the U.S. Department of Health dated Dec 10, 2018, 20% of the gross proceeds from the sale will be payable by the Company to the NIH after closing.
• The agreement includes customary representations, warranties, covenants and indemnification subject to certain limitations and is subject to customary closing conditions, including expiration or termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976; a copy of the PRV asset purchase agreement will be filed with the Company’s Form 10-K for the year ended Dec 31, 2026.

Why it may matter The company reported this under Item 1.01 (entry into a material definitive agreement), which covers material contracts the company has entered into. This filing reports the sale agreement terms, the FDA award date for the PRV, the cash purchase price and the contractual obligation to pay 20% of gross proceeds to the NIH. This filing does not show why the insider traded or why the company acted.